Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients

Background Increasing evidence shows that alterations in gut microbiome (GM) contribute to the development of type 2 diabetes mellitus (T2DM), and fecal microbiota transplantation (FMT) successfully treats various human diseases. However, the benefits of FMT therapy to T2DM patients remain unknown. Methods We enrolled 17 patients with T2DM for nonblinded, one-armed intervention trial of FMT. A total of 20 healthy individuals were recruited as the baseline control. HbA1c% and metabolic parameter change were evaluated in 17 T2DM patients 12 weeks after they received FMT from healthy donors. The GM composition was characterized by 16S rRNA gene amplicon sequencing from fecal samples prior to and 12 weeks after FMT treatment. Results We found that the GM of T2DM patients was reconstituted by FMT. We observed a statistically significant decrease in HbA1c% (from 7.565 ± 0.148 to 7.190 ± 0.210, p<0.01), blood glucose (from 8.483 ± 0.497 to 7.286 ± 0.454 mmol/L, p<0.01), and uric acid (from 309.4 ± 21.5 to 259.1 ± 15.8 µmol/L, p<0.01) while a significant increase in postprandial C-peptide (from 4.503 ± 0.600 to 5.471 ± 0.728 ng/ml, p<0.01) at 12 weeks after FMT. Closely evaluating the changes in these assays, we found individual variability in response to FMT treatment. Out of 17 T2DM patients, 11 were found to significantly improve T2DM symptoms. The FMT responders have significantly higher levels of the family Rikenellaceae and the genus Anaerotruncus (family Ruminococcaceae) in their pretreated fecal in comparison to nonresponders, which could predict the clinical response with an area under the curve of 0.83. Conclusion Our findings suggest that certain T2DM patients can potentially benefit from FMT, and the pretreated abundance of Rikenellaceae and Anaerotruncus in the fecal of patients may serve as potential biomarkers for selecting T2DM patients to receive FMT.

[1]  I. Hirsch,et al.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[2]  A. Zwinderman,et al.  Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial , 2020, Gut.

[3]  F. Hu,et al.  Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. , 2020, Gastroenterology.

[4]  Zhang Faming.  Nanjing consensus on methodology of washed microbiota transplantation , 2020, Chinese medical journal.

[5]  I. García-Pérez,et al.  Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  M. Henn,et al.  Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial , 2020, PLoS medicine.

[7]  A. Gewirtz,et al.  Considering gut microbiota in treatment of type 2 diabetes mellitus , 2020, Gut microbes.

[8]  Zhiguo Wang,et al.  Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets , 2020, Frontiers in Cellular and Infection Microbiology.

[9]  Bota Cui,et al.  Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening , 2020, Protein & Cell.

[10]  R. Rodrigues,et al.  Role of gut microbiota in type 2 diabetes pathophysiology , 2020, EBioMedicine.

[11]  J. Shaw,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.

[12]  Bota Cui,et al.  Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis , 2019, Drug Safety.

[13]  Evgeni Levin,et al.  Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time , 2019, Gut.

[14]  B. Yacyshyn,et al.  Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT) , 2018, Diabetes, obesity & metabolism.

[15]  D. Busch,et al.  An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila , 2018, Digestion.

[16]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[17]  K. Tuttle,et al.  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. , 2018, The lancet. Diabetes & endocrinology.

[18]  M. Hudson.  Human , 2018, Critical Theory and the Classical World.

[19]  Patrice D Cani.  Human gut microbiome: hopes, threats and promises , 2018, Gut.

[20]  Y. Nie,et al.  Microbiota transplantation: concept, methodology and strategy for its modernization , 2018, Protein & Cell.

[21]  M. Boemi,et al.  Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting , 2018, Acta Diabetologica.

[22]  Chenhong Zhang,et al.  Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes , 2018, Science.

[23]  S. Kalra,et al.  EADSG Guidelines: Insulin Therapy in Diabetes , 2018, Diabetes Therapy.

[24]  P. Auvinen,et al.  Gut microbiome in gestational diabetes: a cross‐sectional study of mothers and offspring 5 years postpartum , 2018, Acta obstetricia et gynecologica Scandinavica.

[25]  Evgeni Levin,et al.  Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. , 2017, Cell metabolism.

[26]  F. Alaei-Shahmiri,et al.  Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. , 2017, Microbial pathogenesis.

[27]  E. Barnes,et al.  The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis , 2017, Gut microbes.

[28]  B. Paulweber,et al.  Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. , 2017, Beneficial microbes.

[29]  P. Bork,et al.  Human gut microbes impact host serum metabolome and insulin sensitivity , 2016, Nature.

[30]  A. Haslberger,et al.  Gut Microbiota of Obese, Type 2 Diabetic Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss. , 2016, Endocrine, metabolic & immune disorders drug targets.

[31]  M. Dekker Nitert,et al.  Connections Between the Gut Microbiome and Metabolic Hormones in Early Pregnancy in Overweight and Obese Women , 2016, Diabetes.

[32]  Alexander V. Tyakht,et al.  Gut microbiota and diet in patients with different glucose tolerance , 2015, Endocrine connections.

[33]  D. Fan,et al.  Fecal microbiota transplantation through mid‐gut for refractory Crohn's disease: Safety, feasibility, and efficacy trial results , 2015, Journal of gastroenterology and hepatology.

[34]  B. Shields,et al.  Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine , 2014, PloS one.

[35]  P. Home,et al.  Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? , 2014, Diabetes Care.

[36]  E. Pamer,et al.  Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns , 2014, Mucosal Immunology.

[37]  Dong-Hyun Kim,et al.  High Fat Diet-Induced Gut Microbiota Exacerbates Inflammation and Obesity in Mice via the TLR4 Signaling Pathway , 2012, PloS one.

[38]  M. Blaut,et al.  Role of commensal gut bacteria in inflammatory bowel diseases , 2012, Gut microbes.

[39]  Qiang Feng,et al.  A metagenome-wide association study of gut microbiota in type 2 diabetes , 2012, Nature.

[40]  J. Clemente,et al.  The Impact of the Gut Microbiota on Human Health: An Integrative View , 2012, Cell.

[41]  R. Lorenz,et al.  Gut Microbiota and Obesity , 2012, Current Obesity Reports.

[42]  Jacques Schrenzel,et al.  Responses of Gut Microbiota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-Induced Leptin-Resistant Mice , 2011, Diabetes.

[43]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[44]  P. Strange.  Treat-to-Target Insulin Titration Algorithms When Initiating Long or Intermediate Acting Insulin in Type 2 Diabetes , 2007, Journal of diabetes science and technology.

[45]  G. Charpentier,et al.  Predictors of response to glimepiride in patients with type 2 diabetes mellitus. , 2001, Diabetes & metabolism.

[46]  J. Balfour,et al.  Glimepiride. A review of its use in the management of type 2 diabetes mellitus. , 1998, Drugs.

[47]  A. Motala,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 th edition , 2019 .